CN101903384A - 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物 - Google Patents

作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物 Download PDF

Info

Publication number
CN101903384A
CN101903384A CN2008801218567A CN200880121856A CN101903384A CN 101903384 A CN101903384 A CN 101903384A CN 2008801218567 A CN2008801218567 A CN 2008801218567A CN 200880121856 A CN200880121856 A CN 200880121856A CN 101903384 A CN101903384 A CN 101903384A
Authority
CN
China
Prior art keywords
independently
compound
halogen
optionally
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2008801218567A
Other languages
English (en)
Chinese (zh)
Inventor
J-M·吉米内兹
M·莫蒂默尔
P·克里尔
A·米勒
S·扬
C·梅克
C·戴维斯
H·特温
G·布兰克雷
D·伯雅尔
S·凯利
L·塞迪默
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vertex Pharmaceuticals Inc
Original Assignee
Vertex Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharmaceuticals Inc filed Critical Vertex Pharmaceuticals Inc
Publication of CN101903384A publication Critical patent/CN101903384A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Obesity (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
CN2008801218567A 2007-11-02 2008-10-31 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物 Pending CN101903384A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US98487507P 2007-11-02 2007-11-02
US60/984,875 2007-11-02
US4457508P 2008-04-14 2008-04-14
US61/044,575 2008-04-14
US10080808P 2008-09-29 2008-09-29
US61/100,808 2008-09-29
PCT/US2008/081933 WO2009073300A1 (en) 2007-11-02 2008-10-31 [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta

Publications (1)

Publication Number Publication Date
CN101903384A true CN101903384A (zh) 2010-12-01

Family

ID=40220120

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2008801218567A Pending CN101903384A (zh) 2007-11-02 2008-10-31 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物

Country Status (16)

Country Link
US (2) US8173635B2 (https=)
EP (1) EP2215089B1 (https=)
JP (1) JP5444239B2 (https=)
KR (1) KR20100093552A (https=)
CN (1) CN101903384A (https=)
AR (1) AR069174A1 (https=)
AU (1) AU2008331733A1 (https=)
CA (1) CA2704266A1 (https=)
CL (1) CL2008003280A1 (https=)
ES (1) ES2389992T3 (https=)
IL (1) IL205458A0 (https=)
MX (1) MX2010004819A (https=)
NZ (1) NZ585063A (https=)
TW (1) TW200924762A (https=)
WO (1) WO2009073300A1 (https=)
ZA (1) ZA201003050B (https=)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3456189B2 (ja) 2000-03-31 2003-10-14 日本電気株式会社 移動通信システム
CN102532133A (zh) 2006-01-17 2012-07-04 沃泰克斯药物股份有限公司 适用作詹纳斯激酶抑制剂的吖吲哚类
AU2007338754A1 (en) 2006-12-21 2008-07-03 Vertex Pharmaceuticals Incorporated 5-cyan0-4- (pyrrolo [2, 3B] pyridine-3-yl) -pyrimidine derivatives useful as protein kinase inhibitors
CA2704266A1 (en) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta
WO2009145814A2 (en) * 2008-03-10 2009-12-03 Vertex Pharmaceuticals Incorporated Pyrimidines and pyridines useful as inhibitors of protein kinases
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011001319A (es) * 2008-08-06 2011-04-05 Vertex Pharma Inhibidores de aminopiridina cinasa.
MX2011010058A (es) * 2009-03-25 2011-10-11 Abbott Lab Compuestos antivirales y usos de los mismos.
CA2760705A1 (en) * 2009-05-06 2010-11-11 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
RS57869B1 (sr) 2009-06-17 2018-12-31 Vertex Pharma Inhibitori replikacije virusa gripa
EP2528917B1 (en) * 2010-01-27 2016-10-19 Vertex Pharmaceuticals Incorporated Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases
JP2013518112A (ja) * 2010-01-27 2013-05-20 バーテックス ファーマシューティカルズ インコーポレイテッド ピラゾロピリジンキナーゼ阻害剤
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
WO2011094288A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyrazine kinase inhibitors
EP2566866A1 (en) * 2010-05-05 2013-03-13 Vertex Pharmaceuticals Incorporated 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
AU2011343642A1 (en) 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
CN103492382A (zh) 2010-12-16 2014-01-01 沃泰克斯药物股份有限公司 流感病毒复制的抑制剂
MX2013006840A (es) 2010-12-16 2014-01-31 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
EP2858984A1 (en) 2012-06-08 2015-04-15 Vertex Pharmaceuticals Inc. Inhibitors of influenza viruses replication
EP2951149B1 (en) 2013-01-30 2018-10-10 Ecolab USA Inc. Hydrogen sulfide scavengers
RS59144B1 (sr) 2013-11-13 2019-09-30 Vertex Pharma Inhibitori replikacije virusa influence
HRP20181272T1 (hr) 2013-11-13 2018-10-05 Vertex Pharmaceuticals Incorporated Postupci priprave inhibitora replikacije virusa influence
EP3082819B1 (en) * 2013-12-20 2020-06-17 Signal Pharmaceuticals, LLC Substituted diaminopyrimidyl compounds, compositions thereof, and methods of treatment therewith
TW201613919A (en) 2014-07-02 2016-04-16 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
JP6640840B2 (ja) * 2014-09-22 2020-02-05 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 線維症を処置するための方法及び医薬組成物
EP3286175B1 (en) 2015-04-22 2020-12-02 Ecolab USA Inc. Development of a high temperature stable scavenger for removal of hydrogen sulfide
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤を調製する方法
JP6857617B2 (ja) 2015-05-13 2021-04-14 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ インフルエンザウイルスの複製の阻害剤
AU2016320678B2 (en) 2015-09-08 2021-07-29 Ecolab Usa Inc. Hydrocarbon soluble/dispersible hemiformals as hydrogen sulfide scavengers
US10584286B2 (en) 2015-09-08 2020-03-10 Ecolab Usa Inc. Hydrogen sulfide scavengers
EP3491106B1 (en) 2016-07-29 2020-07-15 Ecolab Usa Inc. Antifouling and hydrogen sulfide scavenging compositions
HRP20220144T1 (hr) * 2016-09-09 2022-04-15 Novartis Ag Spojevi i pripravci kao inhibitori endosomskih toll-u sličnih receptora
WO2019014415A1 (en) 2017-07-13 2019-01-17 Ecolab USA, Inc. METHOD FOR REMOVING A COMPOUND CONTAINING SULFUR BY ADDITION OF A COMPOSITION
EP3914676A1 (en) 2019-01-23 2021-12-01 ChampionX USA Inc. Complete removal of solids during hydrogen sulfide scavenging operations using a scavenger and a michael acceptor
EP3953346A1 (en) 2019-04-09 2022-02-16 Nurix Therapeutics, Inc. 3-substituted piperidine compounds for cbl-b inhibition, and use of a cbl-b inhibitor in combination with a cancer vaccine and/or oncolytic virus
CN111529533B (zh) * 2020-06-05 2021-06-11 南华大学附属第一医院 溴结构域蛋白4抑制剂jq1或其衍生物在制备治疗脓毒症肠屏障损伤药物中的应用
EP4333982A1 (en) * 2021-05-06 2024-03-13 Exscientia Al Limited Pkc-theta modulators
BR112023022883A2 (pt) * 2021-05-06 2024-01-23 Exscientia Ai Ltd Moduladores de pkc-teta

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2080531A (en) * 1936-01-08 1937-05-18 United Shoe Machinery Corp Manufacture of shoes
US3314941A (en) * 1964-06-23 1967-04-18 American Cyanamid Co Novel substituted pyridodiazepins
GB1159487A (en) 1968-04-04 1969-07-23 Standard Telephones Cables Ltd Capacitors
US4988705A (en) * 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
JP2890448B2 (ja) 1988-04-26 1999-05-17 日産化学工業株式会社 ピラゾロピリジン系メバロノラクトン類
US5100768A (en) * 1989-05-09 1992-03-31 Kabushiki Kaisha Toshiba Photosensitive composition
JPH03206450A (ja) * 1990-01-09 1991-09-09 Fuji Photo Film Co Ltd 新規な色素形成カプラー及びそれを用いたハロゲン化銀カラー写真感光材料及びその処理方法
JPH03271289A (ja) 1990-03-16 1991-12-03 Nissan Chem Ind Ltd ピラゾロピリジン誘導体の製造法及びジヒドロピラゾロピリジン誘導体
US5338740A (en) * 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
US5646330A (en) * 1995-02-17 1997-07-08 Ciba-Geigy Corporation Production of enantiomerically enriched ortho-substituted α,α-diaromatic methanols
US6194581B1 (en) * 1995-04-07 2001-02-27 Merck & Co., Inc. Substituted pyridines useful as modulators of acetylcholine receptors
SE9704544D0 (sv) * 1997-12-05 1997-12-05 Astra Pharma Prod Novel compounds
US6452008B2 (en) * 1998-02-25 2002-09-17 Sumitomo Pharmaceuticals Company, Limited Pyridone derivatives and process for preparing the same
GB9908410D0 (en) * 1999-04-13 1999-06-09 Pfizer Ltd Pyridines
PE20010306A1 (es) 1999-07-02 2001-03-29 Agouron Pharma Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa
AR029289A1 (es) * 2000-07-05 2003-06-18 Ishihara Sangyo Kaisha Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su proceso de produccion e intermediario para producirlo
JP2002020386A (ja) 2000-07-07 2002-01-23 Ono Pharmaceut Co Ltd ピラゾロピリジン誘導体
DE10035908A1 (de) * 2000-07-21 2002-03-07 Asta Medica Ag Neue Heteroaryl-Derivate und deren Verwendung als Arzneimittel
WO2002020500A2 (en) * 2000-09-01 2002-03-14 Icos Corporation Materials and methods to potentiate cancer treatment
GB0128287D0 (en) 2001-11-26 2002-01-16 Smithkline Beecham Plc Novel method and compounds
US20030187026A1 (en) * 2001-12-13 2003-10-02 Qun Li Kinase inhibitors
JP2005516927A (ja) * 2001-12-13 2005-06-09 アボット・ラボラトリーズ 癌治療用のキナーゼ阻害剤としての３−（フェニル−アルコキシ）−５−（フェニル）−ピリジン誘導体および関連化合物
DE10222550A1 (de) * 2002-05-17 2003-11-27 Bayer Ag Substituierte Benzyl-pyrazolopyridine
DK1522314T3 (da) * 2002-06-26 2014-05-26 Ono Pharmaceutical Co Midler for sygdomme forårsaget af vaskulær sammentrækning eller udvidelse
EP1545515A1 (en) 2002-08-12 2005-06-29 Sugen, Inc. 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
ATE440087T1 (de) * 2003-01-30 2009-09-15 Boehringer Ingelheim Pharma 2,4-diaminopyrimidinderivate, die sich als inhibitoren von pkc-theta eignen
MXPA05009722A (es) 2003-03-10 2006-03-09 Schering Corp Inhibidores heterociclicos de cinasa: metodos de uso y sintesis.
US20050203067A1 (en) * 2003-05-12 2005-09-15 Hresko Michelle C. Pesticidal compositions and methods
AU2004259755A1 (en) * 2003-07-22 2005-02-03 Janssen Pharmaceutica, N.V. Quinolinone derivatives as inhibitors of c-fms kinase
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
CA2545821C (en) * 2003-12-22 2010-09-21 Basilea Pharmaceutica Ag Aroylfuranes and aroylthiophenes
UY29177A1 (es) 2004-10-25 2006-05-31 Astex Therapeutics Ltd Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos
US7812166B2 (en) * 2004-10-29 2010-10-12 Abbott Laboratories Kinase inhibitors
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
WO2006052568A2 (en) 2004-11-10 2006-05-18 Eli Lilly And Company Tgf-beta inhibitors
DE102004061288A1 (de) * 2004-12-14 2006-06-29 Schering Ag 3-Amino-Pyrazolo[3,4b]pyridine als Inhibitoren von Proteintyrosinkinasen, deren Herstellung und Verwendung als Arzneimittel
PE20061119A1 (es) * 2005-01-19 2006-11-27 Aventis Pharma Sa PIRAZOLO PIRIDINAS SUSTITUIDAS COMO INHIBIDORES DE CINASAS FAK, KDR Y Tie
WO2006101456A1 (en) 2005-03-21 2006-09-28 S*Bio Pte Ltd Bicyclic heterocycles hydroxamate compounds useful as histone deacetylase (hdac) inhibitors
DE602006014540D1 (en) * 2005-05-16 2010-07-08 Irm Llc Pyrrolopyridinderivate als proteinkinaseinhibitoren
AU2006272951A1 (en) 2005-05-17 2007-02-01 Plexxikon, Inc. Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
DE102005035417A1 (de) 2005-07-28 2007-02-01 Robert Bosch Gmbh Entfernungsmessgerät und Verfahren zum Befestigen einer elektrooptischen Einheit an einer Leiterträgereinheit
US7547782B2 (en) 2005-09-30 2009-06-16 Bristol-Myers Squibb Company Met kinase inhibitors
DE102005048897A1 (de) 2005-10-12 2007-04-19 Sanofi-Aventis Deutschland Gmbh Diacylindazol-derivate als Inhibitoren von Lipasen und Phospholipasen
WO2007076423A2 (en) 2005-12-22 2007-07-05 Smithkline Beecham Corporation INHIBITORS OF Akt ACTIVITY
US20070208053A1 (en) * 2006-01-19 2007-09-06 Arnold Lee D Fused heterobicyclic kinase inhibitors
WO2007125321A2 (en) 2006-04-25 2007-11-08 Astex Therapeutics Limited Purine and deazapurine derivatives as pharmaceutical compounds
TW200815438A (en) * 2006-06-13 2008-04-01 Bayer Schering Pharma Ag Substituted pyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same
ATE543819T1 (de) 2006-10-19 2012-02-15 Signal Pharm Llc Heteroarylverbindungen, zusammensetzungen daraus und behandlungsverfahren damit
JP2008132121A (ja) * 2006-11-28 2008-06-12 Sanshin Kinzoku Kogyo Kk 移動ラック装置
WO2008079292A1 (en) 2006-12-20 2008-07-03 Amgen Inc. Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer
WO2008132121A1 (en) * 2007-04-26 2008-11-06 Glaxo Group Limited Lh-indazole-3-amine compounds as ikk1 inhibitors
CA2704266A1 (en) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1h- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase c-theta

Also Published As

Publication number Publication date
EP2215089B1 (en) 2012-06-27
US20120149680A1 (en) 2012-06-14
IL205458A0 (en) 2010-12-30
ES2389992T3 (es) 2012-11-05
AR069174A1 (es) 2010-01-06
NZ585063A (en) 2012-05-25
EP2215089A1 (en) 2010-08-11
JP2011502994A (ja) 2011-01-27
WO2009073300A1 (en) 2009-06-11
KR20100093552A (ko) 2010-08-25
CL2008003280A1 (es) 2010-01-04
US8367697B2 (en) 2013-02-05
US20090291937A1 (en) 2009-11-26
TW200924762A (en) 2009-06-16
ZA201003050B (en) 2011-07-27
AU2008331733A1 (en) 2009-06-11
CA2704266A1 (en) 2009-06-11
MX2010004819A (es) 2010-07-05
US8173635B2 (en) 2012-05-08
JP5444239B2 (ja) 2014-03-19

Similar Documents

Publication Publication Date Title
CN101903384A (zh) 作为蛋白激酶Cθ抑制剂的[1H-吡唑并[3,4-B]吡啶-4-基]-苯基或-吡啶-2-基衍生物
CN102131807B (zh) 吡唑并吡啶激酶抑制剂
EP2318408B1 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
US9193722B2 (en) Tri-cyclic pyrazolopyridine kinase inhibitors
US8541445B2 (en) Pyrazolopyridines
AU2009274017A1 (en) Pyrazolopyridine kinase inhibitors
WO2011139273A1 (en) 4 substituted pyrazolopyrimidines useful as pkc-theta inhibitors
EP2528917B1 (en) Pyrazolopyridines useful for the treatment of autoimmune, inflammatory or (hyper)proliferative diseases
CA2787321A1 (en) Pyrazolopyridine kinase inhibitors
CN102159546A (zh) 氨基吡啶激酶抑制剂
CN102869663A (zh) 吡唑并吡嗪激酶抑制剂
HK1145681A (en) [1h-pyrazolo[3,4-b]pyridine-4-yl]-phenyle or-pyridin-2-yle derivatives as protein kinase c-theta
AU2015201376A1 (en) Pyrazolopyridine kinase inhibitors
HK1156026B (en) Pyrazolopyridine kinase inhibitors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1145681

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20101201

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1145681

Country of ref document: HK